

related recombinant allergens which discriminate with 100% specificity between ABPA and allergic sensitization to *A. fumigatus*.--

- 15. (NEW) The method according to claim 14, wherein the allergen is derived from *A. fumigatus*.--
- 16. (NEW) The method according to claim 15, wherein the allergen corresponds to a non-secreted protein from *A. fumigatus*.--
- 17. (NEW) The method according to claim 14, wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens.--
- 18. (NEW) The method according to claim 17, wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.--
- 19. (NEW) The method according to claim 17, wherein antibodies of the IgE class are determined.--
- 20. (NEW) The method according to claim 14, wherein an in vivo test is carried out in the individual.--
- 21. (NEW) The method according to claim 20, wherein the test is a skin test involving placing said one or more ABPA-related recombinant allergens in the skin of the patient.--
- 22. (NEW) The method according to claim 20, wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.--
- 23. (NEW) The method according to claim 20, wherein antibodies of the IgE class are determined.--